BWX Technologies (BWXT) investor relations material

Strategic overview and market positioning

• Positioned as a global nuclear industrial leader with over 70 years of experience, a workforce of ~11,000, and $3.8B in 2026 sales, up 19% YoY and 41% since early 2024.

• Expanded manufacturing footprint to 16 sites, including major expansions and acquisitions, supporting unmatched scale and capabilities.

• Commercial business now 30% of revenue, up from 20% five years ago, and is the fastest-growing segment.

• Only commercial entity with a Category 1 NRC license, enabling unique access to special nuclear materials.

• Backlog more than doubled since 2023, reaching $8.4B by mid-2026, providing nine quarters of visibility and supporting aggressive growth targets.

Business segment developments and growth drivers

• Commercial segment transformed from CANDU-focused to a global merchant supplier, expecting >$1.2B revenue in 2026 and a robust $1.6B backlog.

• Service revenue in Commercial grew from $70M in 2020 to $600M in 2026, driven by acquisitions and organic growth.

• Government Operations revenue at $2.6B, with 425 reactors delivered and 6,000 employees; naval propulsion remains core, but special materials and advanced nuclear are fastest-growing.

• Special materials segment rapidly expanding, with high-purity depleted uranium and enrichment contracts totaling over $3B.

• Advanced nuclear business scaling up, delivering microreactors (Pele, Janus) and leading in TRISO fuel production.

Financial guidance and capital allocation

• 2030 targets: $5.5B–$6B revenue, $1.1B–$1.2B adjusted EBITDA, $525M–$575M free cash flow; low double-digit annual revenue growth expected.

• Adjusted EBITDA margin to rise from 17.5% in 2026 to ~20% by 2030, driven by operational excellence, pricing, and scale.

• CapEx to remain at 5%–6% of revenue, with over $2B cumulative free cash flow and $5.5B available capital for deployment through 2030.

• Disciplined M&A and portfolio management, with recent acquisitions (AOT, Kinectrics, PCG) and divestiture of majority stake in medical business for $800M.

• Balance sheet strengthened with $1.25B convertible notes, $1.7B liquidity, and investment-grade rating from Fitch.